Smith v. Antares Pharma, Inc., 2020 WL 2041752 (D.N.J. Apr. 28, 2020)
Judge Michael A. Shipp of the District of New Jersey dismissed a putative class action complaint filed against Antares Pharma, Inc., and certain of its officers, holding that
Life Sciences Securities Litigation
The Life Sciences Securities Litigation blog, published by Ropes & Gray, focuses on legal issues related to securities class actions and regulatory enforcement affecting companies in the life sciences sector, including pharmaceutical, biotechnology, and medical device firms. It covers trends in securities litigation targeting life sciences companies, False Claims Act settlements, whistleblower cases, and compliance challenges such as kickback allegations and Medicaid rebate disputes. The blog also addresses large-scale settlements involving opioid litigation and other significant regulatory developments impacting life sciences corporations. It serves as a resource for understanding litigation risks, disclosure obligations, and strategies for managing securities and regulatory exposures in the life sciences industry.
Latest from Life Sciences Securities Litigation - Page 3
First Circuit Affirms Dismissal of Action Regarding Statements Concerning Manufacturing of Eye Drug
Mehta v. Ocular Therapeutix, Inc., 955 F.3d 194 (1st Cir. 2020)
On April 9, 2020, the First Circuit affirmed the dismissal of an action brought against a biopharmaceutical company, Ocular Therapeutix, Inc., and certain of its officers, regarding statements concerning…
S.D.N.Y. Dismisses Action due to Plaintiffs’ Failure to Link Occurrences of Serious Adverse Events to Liver Disease Drug
Hou Liu v. Intercept Pharm., Inc., 2020 WL 1489831 (S.D.N.Y. Mar. 26, 2020)
On March 26, 2020, Judge Lewis A. Kaplan of the Southern District of New York granted a motion to dismiss an action against Intercept Pharmaceuticals, Inc. and…
Cornerstone Research Report Shows Continued Rate of Federal Securities Litigation Filings Targeting Pharmaceutical Industry
A recently-published annual report from Cornerstone Research demonstrates the continued focus by the plaintiffs’ securities litigation bar on pharmaceutical, healthcare, and biotechnology firms.
The report notes that 2019 federal securities filings (excluding merger objections), against Consumer Non-Cyclical companies, primarily composed…
District Court Judge Partially Dismisses Claims Against Celgene, But Allows Allegations Regarding Misleading Statements About Sales Projections and FDA Approval to Proceed
In re Celgene Corp. Sec. Litig., 2019 WL 6909463 (D.N.J. Dec. 19, 2019)
On December 19, 2019, Judge John Michael Vazquez of the District of New Jersey partially denied a motion to dismiss a putative securities class action complaint filed…
District of New Jersey Dismisses Action For Failure to Allege Materiality of Non-Disclosure of a Conflict of Interest
Biondolillo v. Roche Holding AG, 2019 WL 2498928 (D.N.J. June 17, 2019)
On June 17, 2019, Senior Judge Anne E. Thompson granted a motion to dismiss an action alleging that Roche Holding AG and four executives misled investors by failing…
District Judge Finds Error in Previous Dismissal of Action Against Acquirer of Blood Testing Manufacturer
Forman v. Meridian Bioscience, 2019 WL 2177030 (S.D. Ohio May 20, 2019)
On May 20, 2019, Judge Susan J. Dlott of the Southern District of Ohio granted plaintiff’s motion to reconsider and amend a prior order dismissing an action against…
D. Mass Holds Plaintiffs Failed to Plead Securities Law Violation Regarding Company’s Statements Concerning Manufacturing of Eye Drug
In re: Ocular Therapeutix, Inc. Sec. Litig. 2019 WL 1950399 (D. Mass. Apr. 30, 2019)
Judge George O’Toole of the U.S. District Court for the District of Massachusetts dismissed a putative securities class action complaint filed against a biopharmaceutical company,…
S.D.N.Y. Dismisses Investor Suit Concerning Pancreatic Cancer Drug Study
Nguyen v. New Link Genetics Corp., 2019 WL 591556 (S.D.N.Y. Feb. 13, 2019)
On February 13, 2019, Judge William H. Pauley, III of the Southern District of New York dismissed a proposed investor class action against New Link Genetics Corporation.…
NERA Report Shows Continued Focus of Plaintiffs’ Securities Bar on the Pharmaceutical Industry
The recent annual report from NERA Economic Consulting demonstrates the continued focus by the plaintiffs’ securities litigation bar on health care and life science firms, particularly those focused on the development and commercialization of drugs and devices.
The Report found…